

July 8, 2020

James A. Hayward Chairman, President & CEO Applied DNA Sciences 50 Health Sciences Drive Stony Brook, NY 11790

Re: EUA200474/A002

Trade/Device Name: Linea COVID-19 Assay Kit

Dated: June 21, 2020 Received: June 22, 2020

Dear Dr. Hayward:

This is to notify you that your request to update the Instructions for se (IFU) a COVID-19 Assay Kit to; (1) include use of the manual RNA extraction kit, Omega Bio-Tek Mag-I nd Viral RN ress Kit, and (2) include minor edits in the IFU for clarification is granted. Upon review, we ata and information submitted in EUA200474/A002 supports the requested updates for use with the nea COVID-19 Assay Kit. FDA also requested minor updates to the "Intended Use", "Warnings and "Limitations" sections of the IFU to reflect language used in more recently issued Emergency ons. A also updated the Healthcare Provider se Authoriza and Patient Fact Sheets accordingly. By submitting t for review by the Food and Drug Administration is amendme (FDA), you have complied with the Conditions orization s ted in the letter authorizing the emergency use of the Linea COVID-19 Assay Kit issued on May 13

Si cerely yours,

Uwe Scherf, M.Sc., Ph.D.

Director, Division of Microbiology Devices

OHT7: Office of In Vitro Diagnostics and Radiological Health

Office of Product Evaluation and Quality Center for Devices and Radiological Health